Regards drug reimbursements made to 340B covered entities

HB 588 prohibits drug manufacturers and wholesalers from denying, restricting, or discriminating against 340B covered entities when they attempt to acquire discounted drugs. The bill also forbids these entities from requiring the submission of utilization data as a condition for purchasing these drugs unless such data sharing is already mandated by federal law. Violations of these rules are classified as unlawful practices, allowing the state attorney general to enforce compliance and impose civil penalties of up to $50,000 for each violation. Additionally, the attorney general may refer complaints to the state board of pharmacy for further disciplinary action. This legislation ensures that entities participating in the federal 340B drug pricing program face no additional barriers or data requirements when obtaining covered outpatient medications.